文献速递甲状腺疾病

仑伐替尼治疗甲状腺癌期间的症状性胆道疾病:一个被低估的问题

Symptomatic Biliary Disorders During Lenvatinib Treatment for Thyroid Cancer: An Underestimated Problem.
PubMed 文献 · Thyroid · 2020-01-28

该回顾性研究纳入本中心连续接受仑伐替尼治疗的放射性碘难治性分化型甲状腺癌患者,排除治疗前已行胆囊切除术者。5例(14.7%)在中位4.4个月后出现经影像学确认的症状性胆道疾病并接受胆囊切除术,作者认为该比例意外偏高,需进一步研究优化诊断与治疗。

要点

  • 5例(14.7%)患者出现经影像学确认的症状性胆道疾病并接受胆囊切除术。
  • 从开始仑伐替尼治疗至出现胆道疾病的中位时间为4.4个月(四分位距3.4-14.4个月)。
  • 仅2例能按计划手术,其余患者术前酪氨酸激酶抑制剂中断不足一周,伤口愈合后全部恢复治疗。

核心结论

  • 在本队列中,接受仑伐替尼治疗的放射性碘难治性分化型甲状腺癌患者出现需手术干预的症状性胆道疾病的比例意外偏高。
  • 作者指出需进一步研究以优化对仑伐替尼治疗期间高风险发生症状性胆囊或胆道疾病患者的诊断与治疗。

研究设计与样本

  • 回顾性评估本中心所有连续接受仑伐替尼治疗的进展性放射性碘难治性分化型甲状腺癌患者,排除开始治疗前已行胆囊切除术者。
  • 报告所有经影像学确认并随后接受胆囊切除术的症状性胆囊或胆道疾病,描述其管理及相关的生化和组织学发现。
  • 所有出现胆道毒性患者的胆囊或胆道影像由一位经验丰富的放射科医生复核,包括基线和酪氨酸激酶抑制剂治疗期间为肿瘤评估所做的计算机断层扫描。

主要发现

  • 5例患者(14.7%)在仑伐替尼治疗中位4.4个月后出现经影像学确认的症状性胆道疾病并接受胆囊切除术,四分位距3.4-14.4个月。
  • 仅2例能按计划进行手术,其余患者术前酪氨酸激酶抑制剂中断时间不足一周。
  • 所有患者在伤口愈合后恢复治疗。
  • 3例患者在之前两个月的月度随访中显示轻度生化异常。
  • 治疗开始前,仅1例经影像学检测到胆囊或胆道异常。

临床怎么用

  • 作者认为需进一步研究以优化对仑伐替尼治疗期间高风险发生症状性胆囊或胆道疾病患者的诊断与治疗。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Background: The prognosis of several human malignancies has dramatically improved after the introduction of tyrosine kinase inhibitors (TKIs); however, their use has been associated with a large spectrum of adverse events, including symptomatic biliary disorders. In the phase III trial of lenvatinib in radioactive iodine (RAI)-refractory differentiated thyroid cancer (DTC) patients, gallbladder (GB) and biliary duct (BD) diseases and complications were reported. We evaluated symptomatic biliary disorders during treatment with lenvatinib in real-life practice to provide a more exhaustive understanding of its toxicity. Methods: We retrospectively evaluated all consecutive patients treated with lenvatinib in our center for progressive RAI-refractory DTC, excluding those who underwent cholecystectomy before the start of therapy. We report all radiologically confirmed symptomatic GB/BD disorders, which were subsequently treated with cholecystectomy, and we describe their management along with relevant biochemical and histological findings. All available GB/BD imaging of patients who developed biliary toxicity during lenvatinib was reviewed by a single experienced radiologist, including computed tomography scans performed for tumor assessment at baseline and during TKI therapy. Results: Five patients (14.7%) developed symptomatic radiologically confirmed biliary disease after a median time of 4.4 months of lenvatinib treatment [interquartile range 3.4-14.4 months] and thus underwent cholecystectomy. A scheduled surgical approach was possible only in two cases; in the remaining patients, presurgical TKI interruption was shorter than one week. After wound healing, treatment was resumed by all subjects. Three patients showed mild biochemical alterations in the two previous monthly follow-up visits. Before the start of treatment, GB/BD abnormalities were radiologically detected only in one case. Conclusions: In our cohort, an unexpectedly high proportion of RAI-refractory DTC patients treated with lenvatinib developed a symptomatic biliary disorder with the need of surgical intervention. Further studies are required to optimize the diagnosis and treatment of patients at higher risk of developing a symptomatic GB/BD disease during assumption of lenvatinib.

来源:Thyroid,查看原文。版权归原作者所有。

引用

  1. Nervo A, Ragni A, Gallo M, et al. Symptomatic Biliary Disorders During Lenvatinib Treatment for Thyroid Cancer: An Underestimated Problem. Thyroid. 2020. PMID: 31854230. doi:10.1089/thy.2019.0355

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。